In the Press
February 6, 2024

Novo Holdings Buying Biopharma Co Catalent In $16.5 Billion Deal (Law360)

Novo Holdings, the controlling shareholder in Novo Nordisk Foundation, said Monday it has agreed to acquire Catalent in an all-cash transaction that values the pharmaceutical company at $16.5 billion. Novo will acquire all outstanding shares of Catalent for $63.50 per share in cash, a 16.5% premium to Catalent closing price Friday, according to Law360. Catalent's stock jumped about 8.6% to $59.25 per share in premarket trading Monday. The Goodwin team advising Novo Holdings includes Private Equity partner Matt Mauney and Merger and Acquisitions co-chair Joshua Zachariah.